2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2004060505v1 16/2/474    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Esnault, V. L.M. Articles by Nguyen, J.-M. Search for Related Content PubMed PubMed Citation Articles by Esnault, V. L.M. Articles by Nguyen, J.-M. Related Collections Related Article

Diuretic and Enhanced Sodium Restriction Results in Improved Antiproteinuric Response to RAS Blocking Agents

¹ Nephrology and Clinical Immunology Department, Nantes University Hospital, Nantes, France

Address correspondence to: Dr. Vincent Esnault, Service de Néphrologie et Immunologie Clinique, CHU de Nantes, 30 Boulevard Jean Monnet, 44093 Nantes, France. Phone: 33-240087454; Fax: 33-240084660; vesnault{at}nantes.inserm.fr

Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and diuretics may exert synergistic antiproteinuric effects. Eighteen patients with a proteinuria >1 g/24 h after 6 mo of treatment with ramipril at 5 mg/d were assigned to receive in random order ramipril at 10 mg/d, valsartan at 160 mg/d, or combined ramipril at 5 mg/d and valsartan at 80 mg/d in addition to their antihypertensive treatment. The treatment periods lasted 4 wk and were separated by a 4-wk washout with ramipril at 5 mg/d. At the end of this crossover sequence, patients received combined ramipril at 5 mg/d, valsartan at 80 mg/d, and an increased furosemide dosage for an additional 4-wk period. The primary end point was the urinary protein/creatinine ratio for two 24-h urine collections at the end of each treatment period. No significant differences were noted between the study end points of the ramipril 10, valsartan 160, and combined ramipril 5 and valsartan 80 treatment groups. However, the urinary protein/creatinine ratio was lower with combined ramipril 5 and valsartan 80–increased furosemide dosage than with valsartan 160 and combined ramipril 5 and valsartan 80, with a similar tendency compared with ramipril 10. Combined ramipril 5 and valsartan 80–increased furosemide dosage decreased systolic home BP and increased serum creatinine but did not significantly increase the number of symptomatic hypotension cases compared with the other three treatments. Thus, in patients with severe proteinuria and hypertension, a cautious increase in diuretic dosage in addition to combined angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decreases proteinuria and BP but may expose the patient to prerenal failure.

Related Article

This Month’s Highlights
J. Am. Soc. Nephrol. 2005 16: 279-283. [Full Text] [PDF]

This article has been cited by other articles:

				L. Vogt, F. Waanders, F. Boomsma, D. de Zeeuw, and G. Navis Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan J. Am. Soc. Nephrol., May 1, 2008; 19(5): 999 - 1007. [Abstract] [Full Text] [PDF]

				R. Kunz, C. Friedrich, M. Wolbers, and J. F.E. Mann Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria in Renal Disease Ann Intern Med, January 1, 2008; 148(1): 30 - 48. [Abstract] [Full Text] [PDF]

				S. L. Linas Are Two Better Than One? Angiotensin-Converting Enzyme Inhibitors Plus Angiotensin Receptor Blockers for Reducing Blood Pressure and Proteinuria in Kidney Disease Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(Supplement_1): S17 - S23. [Abstract] [Full Text] [PDF]

				A. Chrysostomou, E. Pedagogos, L. MacGregor, and G. J. Becker Double-Blind, Placebo-Controlled Study on the Effect of the Aldosterone Receptor Antagonist Spironolactone in Patients Who Have Persistent Proteinuria and Are on Long-Term Angiotensin-Converting Enzyme Inhibitor Therapy, with or without an Angiotensin II Receptor Blocker Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 256 - 262. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673